Fox Chase Cancer Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Fox Chase Cancer Center sits in the top decile of US sponsors by registered trial count (#164 of 15,742 sponsors by registered trial count).
Fox Chase Cancer Center: 183 sponsored US clinical trials, 29 recruiting.
Fox Chase Cancer Center sponsors 183 registered US clinical trials on ClinicalTrials.gov, 29 of them currently recruiting, and 104 completed. 5 of these trials are in Phase 3-4 (later-stage) and 107 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Urothelial Carcinoma, with 6 trials.
Top-decile sponsor footprint
Fox Chase Cancer Center ranks in the top decile of sponsors by registered trial count (#164 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
104 of 137 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (75.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
183 total, page 2 of 4
Liver Cancer Community Education
NCT04272619
Clinician Communication About Sexual Health
NCT04262219
Coping Together After Breast Cancer
NCT03930797
Utility of CAML as Diagnostic for Early Stage Lung Cancer
NCT03992183
Atorvastatin ± Aspirin in Lynch Syndrome Syndrome
NCT04379999
Mychoice: Testing an Interactive mHealth Tool
NCT03427177
Addressing Sexual Concerns in Breast Cancer: Patient Intervention Study
NCT03624972
Molecular Monitoring With Circulating Tumor DNA and Nivolumab Maintenance
NCT03311958
Pilot Study to Investigate The Diagnostic Yield and Utility of 22g and 19g Endobronchial Ultrasound Transbronchial Needle Aspirate
NCT03311620
Impact of Ribociclib on Head and Neck Squamous Cell Cancer
NCT03179956
Depletion of Myeloid Derived Suppressor Cells to Enhance Anti PD-1 Therapy
NCT03302247
VM110 in Detection of Microscopic Tumors: A Phase I Study
NCT03286062
Regorafenib Plus 5-Fluorouracil/Leucovorin Beyond Progression in mCRC
NCT03099486
Trial Using Octreotide to Enhance Liver Recovery After Hepatectomy
NCT03179995
Single Agent ONC201 in Recurrent or Metastatic Endometrial Cancer
NCT03099499
Safety and Activity of Digoxin With Decitabine in Adult AML and MDS
NCT03113071
Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer
NCT02963610
Observation Study of Patients With Non-Small Cell Lung Cancer and Esophageal Cancer Treated With Chemo-Radiation Followed by Surgery
NCT03095209
A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma
NCT02616965
Study of TAK-228 (MLN0128) in Soft Tissue Sarcomas
NCT02987959
Fitbit Assessed PS in Colorectal Cancer
NCT07084181
Improving the Approach to and Management of the Older Metastatic Breast Cancer Patient
NCT03007641
A Study of Pembrolizumab in Patients With Neuroendocrine Tumors
NCT02939651
Next Generation Sequence Target-Directed Therapy in Treating Patients With Cancer
NCT02132845
A Biobehavioral Model of Diabetes Risk in Chinese Immigrants
NCT02449213
Feasibility Bowel Dysfunction Program After Low Anterior Resection
NCT04733794
Irinotecan-Eluting Beads in Treating Patients With Refractory Metastatic Colon or Rectal Cancer That Has Spread to the Liver
NCT02110953
Quinacrine-Capecitabine Combinatorial Therapy for Advanced Stage Colorectal Adenocarcinoma
NCT01844076
Study of MK-3475 Alone or in Combination With Copanlisib in Relapsed or Refractory NK and T-cell Non-Hodgkin Lymphoma
NCT02535247
Combination of Interferon-gamma and Nivolumab for Advanced Solid Tumors
NCT02614456
Bicalutamide With or Without Metformin for Biochemical Recurrence in Overweight or Obese Prostate Cancer Patients
NCT02614859
Investigation of Contralateral Arytenoid Sparing IMRT for T1a & T2a Larynx Cancer & Analysis of Post-treatment Laryngeal Function
NCT02633540
A Dose-Escalation Study of Onc201 Administered Every One or Three Weeks in Advanced Solid Tumors and Multiple Myeloma
NCT02609230
Pilot Study of an Intimacy Enhancement Intervention for Couples Facing Breast Cancer
NCT02721147
Sporadic Angiomyolipomas (AMLs) Growth Kinetics While on Everolimus
NCT02539459
Study of Ixazomib With Pegylated IFN-alpha 2b (pIFN) in Metastatic Renal Cell Carcinoma (mRCC)
NCT02447887
Genetic Sequencing-Informed Targeted Therapy in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer
NCT02132884
Genetic Mutations in Blood and Tissue Samples in Predicting Response to Treatment in Patients With Locally Advanced Rectal Cancer Undergoing Chemoradiation
NCT02132858
Technology and Health Communication in Improving Health Outcomes in Patients Scheduled for Mammography
NCT04290585
PET-CT in Determining the Radioembolization Dose Delivered to Patients With Liver Metastasis, Primary Liver Cancer, or Biliary Cancer
NCT02088775
Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT01962948
Telomere Length in Predicting Toxicity in Older Patients With Stage III-IV Colorectal Cancer Undergoing Chemotherapy
NCT01934179
A Pilot Study of a Home-Based Walking Intervention for Pancreatic Cancer Patients
NCT02442323
Chemoradiation and Radiosurgery Boost in Treating Patients With Locally Advance Pancreatic Cancer That May or May Not be Removed by Surgery
NCT01739439
SMART Project in Preventing Skin Cancer
NCT03177057
Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDS
NCT02190695
Adherence to Survivorship Care Guidelines in Health Care Providers for Non-Small Cell Lung Cancer and Colorectal Cancer Survivor Care
NCT01726296
Study to Evaluate NA-NOSE for Monitoring and Detecting Recurrence in Early Stage Lung Cancer
NCT01840150
A Web-Based Multimedia Intervention for Head and Neck Cancer Patients
NCT02442336
Gemcitabine Hydrochloride and Cisplatin Before Surgery in Treating Patients With Muscle Invasive Bladder Cancer
NCT01611662
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 45 |
| Phase 2 | 62 |
| Phase 3 | 4 |
| Phase 4 | 1 |
Therapeutic Areas
What is open in the Fox Chase Cancer Center pipeline
29 recruiting of 183 indexed (16% open); 104 completed (57%).
Phase mix: 5 late (III/IV) vs 107 early (I/II) (early-phase heavy).
Top condition: Urothelial Carcinoma (6 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Fox Chase Cancer Center: open-pipeline peers nationwide
Peers matched on 183 registered trials and 16% open enrollment, not the therapeutic-area sidebar.
Fox Chase Cancer Center sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 183 trials (± recruiting share)
- Children's Mercy Hospital Kansas City · 184 trials · 11% recruiting
- ViiV Healthcare · 182 trials · 4% recruiting
- Boston University · 185 trials · 12% recruiting
- National Human Genome Research Institute (NHGRI) · 185 trials · 16% recruiting
Sponsors near 16% open enrollment (± trial volume)
- University of Oregon · 16% recruiting · 63 trials
- University of California, San Francisco · 16% recruiting · 1,713 trials
- Youngstown State University · 16% recruiting · 19 trials
- University of Southern California · 16% recruiting · 617 trials
Related
What to do with this Fox Chase Cancer Center page
183 registered trials is a research-attention snapshot, not an endorsement of Fox Chase Cancer Center or any single study.
- 29 of Fox Chase Cancer Center's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Urothelial Carcinoma is the condition Fox Chase Cancer Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Urothelial Carcinoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Fox Chase Cancer Center pipeline card: 183 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.